Abstract
Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.
Original language | English |
---|---|
Article number | e00035-17 |
Journal | Infection and Immunity |
Volume | 85 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 1 2017 |
Bibliographical note
Funding Information:This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services.
Publisher Copyright:
© 2017 American Society for Microbiology.
Keywords
- Pneumocystis carinii
- Vaccines
ASJC Scopus subject areas
- Parasitology
- Microbiology
- Immunology
- Infectious Diseases